Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could ditching Beta-Blockers boost heart Patients' exercise?

NCT ID NCT05019027

Symptom relief Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This study looks at whether older adults with a heart condition called cardiac amyloidosis feel better and can exercise more when they stop taking beta-blockers. Twenty participants will each go through two periods: one on their beta-blocker and one off it. Researchers will measure exercise capacity and quality of life to see if stopping the drug makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
beta blocker
What this could lead to
If successful, this could show that stopping beta-blockers helps some patients with cardiac amyloidosis feel better and exercise more.
What could go wrong
This is a very small, early-phase study with only 20 participants. Results may not apply to everyone, and stopping beta-blockers carries risks like heart rate changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

14 people

The number who actually took part.

Started

Jan 2024

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Ambulatory adults age ≥65 years with TTR-cardiac amyloidosis (confirmed by PYP scan or biopsy) 2. Taking beta-blocker Exclusion Criteria: 1. Other compelling indication(s) for beta-blockers: 1. Angina 2. Acute coronary syndrome, myocardial infarction or coronary artery bypass surgery in prior 3 years 3. Atrial arrhythmia with hospitalization for rapid ventricular response, prior 1 year 4. Heart rate \>100 bpm within the prior 3 months 5. Atrial arrhythmia with ventricular rate \>90 beats per minute within the prior 3 months 6. Systolic blood pressure readings \>160 mmHg within the prior 1 month, unless classified as white coat hypertension/effect (e.g., migraine prevention, anxiety symptom management, hyperthyroidism, essential tumor reduction) 2. Clinical instability (N-of-1 trials are appropriate for stable conditions only) 1. Decompensated heart failure 2. Hospitalized in the past 30 days 3. Medication changes or procedures in the prior 14 days that could confound observations/data at Principal Investigator discretion 4. Anticipated medication changes or procedures in subsequent 3 months that could confound observations/data at PI discretion 5. Clinical instability from other medical issues 3. Estimated life expectancy \<6 months 4. Moderate-severe dementia or psychiatric disorder precluding informed consent 5. Language barrier that will preclude informed consent and ability to comprehend study procedures 6. Non-compliance or inability to complete study procedures 7. Enrollment in a clinical trial not approved for co-enrollment 8. Any condition that, in Principal Investigator or treating physician's opinion, makes the patient unsuitable for study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac amyloidosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Amyloid Neuropathies, Familial amyloidosis heart disorder heart failure wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac amyloidosis Heart diseases TTR cardiac amyloidosis

Contacts and locations

Locations

  • Weill Cornell Medicine

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.